Intrathecal dexmedetomidine for cesarean delivery and postoperative outcomes: a single-center retrospective cohort study (2019–2020)
Main finding · Postoperative pain scoreResult — go to the resultEffect size −0.41 95% CI −0.18 to −0.64Authors' conclusion
Intrathecal dexmedetomidine 10 µg was associated with reduced postoperative pain and opioid use, supporting its role as an intrathecal adjuvant.
Study context
- Population
- Cesarean deliveries under spinal anesthesia at a community hospital, 2019–2020 (excluding epidural labor analgesia, GA, intrathecal catheters)of 572 screened
- Participants
- 414 participants
- Exposure
- Dexmedetomidine vs No dexmedetomidine
- Dexmedetomidinen = 163
- No dexmedetomidinen = 251reference
- Outcome
- Postoperative pain score
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Effect size
−0.41
95% CI −0.18 to −0.64
P < 0.001
Observational data: associations, not effects.
Secondary outcomes
| Outcome | P value |
|---|---|
| Opioid use (MME) · 0-6 h after anesthesiaSignificantly reduced | P < 0.001 |
| Opioid use (MME) · 6-24 h after anesthesia endSignificantly reduced | P = 0.0465 |
Opioid use (MME) · 0-6 h after anesthesia
- Opioid use 15.0 mg vs. 22.5 mg
Opioid use (MME) · 6-24 h after anesthesia end
- Opioid use 26.1 mg vs. 29.4 mg
Safety
| Outcome | P value |
|---|---|
| Intraoperative hypotensionHigher incidence | P < 0.001 |
Intraoperative hypotension
- Incidence 44.2% vs. 28.3%
Original publication
Intrathecal dexmedetomidine for cesarean delivery and postoperative outcomes: a single-center retrospective cohort study (2019–2020). Int J Obstet Anesth. Published 14 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →